Previous studies have shown that therapeutic inhibition of IDO, CTLA-4, or PD-L1 in mouse glioma models significantly reduces the number of tumor-infiltrating Treg cells and substantially improves long-term survival. The gene discussed is IDO1; the disease is central nervous system cancer.